Advertisement

Hepatorenal Failure

  • K. Lenz
  • C. Kapral
  • N. P. Linz

Abstract

The hepatorenal syndrome is a fully reversible impairment of renal function in patients with severe hepatic failure (Table 1). Before hepatorenal syndrome can be diagnosed, primary causes such as hypovolemia, infection, nephrotoxins and other renal diseases must be excluded [1]. Hepatorenal syndrome causes no morphological changes in the kidney, although morphological alterations in the course of oligoanuria may reveal a transition from intermediary to irreversible kidney damage with necrosis of the tubule. In patients with hepatorenal syndrome who are scheduled for liver transplantation, this may raise the relevant issue of simultaneous kidney transplantation.

Keywords

Transjugular Intrahepatic Portosystemic Shunt Hepatorenal Syndrome Venous Compliance Renal Circulation Cardiac Sympathetic Nerve Activity 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Arroyo V, Gines P, Gerbes AL, et al (1996) Definition and diagnostic criteria of refractory ascites and hepatorenal syndrome in cirrhosis. Hepatology 23: 164–173PubMedCrossRefGoogle Scholar
  2. 2.
    Moore K (1997) The hepatorenal syndrome Clin Sci 92: 433–443Google Scholar
  3. 3.
    Cardoso JE, Gautreau C, Jeyaraj PR, et al (1994) Augmenation of portal blood flow improves function of human cirrhotic liver. Hepatology 19: 375–380PubMedCrossRefGoogle Scholar
  4. 4.
    Lang F, Tschernko E, Schulze E, et al (1991) Hepatorenal reflex regulationg kidney function. Hepatology 14: 590–594PubMedCrossRefGoogle Scholar
  5. 5.
    Kostreva DR, Castaner A, Kampine JP (1980) Reflex effects of hepatic baroreceptors on renal and cardiac sympathetic nerve activity. Am J Physiol 238: R390–R394PubMedGoogle Scholar
  6. 6.
    Levy M, Wexler MJ (1987) Hepatic denervation alters first phase urinary sodium excretion in dogs with cirrhosis. Am J Physiol 253: F664–F671PubMedGoogle Scholar
  7. 7.
    Solis-Herruzo JA, Duran A, Favela V, et al (1987) Effects of lumbar sympathetic block on kidney function in cirrhotic patients with hepatorenal syndrome. J Hepatol 5: 167–173PubMedCrossRefGoogle Scholar
  8. 8.
    Hadengue A, Moreau R, Gaudin C, Bacq Y, Chamigneulle B, Lebrec D (1992) Total effective compliance in patients with cirrhosis: A study to the response to acute blood volume expansion. Hepatology 15: 809–815Google Scholar
  9. 9.
    Kirchheim HR, Ehmke H (1994) Vasoactive hormones: modulators of renal function. Clin Invest 72: 685–687CrossRefGoogle Scholar
  10. 10.
    Persson PB, Ehmke H, Nafz B, Kirchheim RH (1990) Sympathetic modulation of renal autoregulation by carotid occlusion in conscious dog. Am J Physiol 258: F364–F370PubMedGoogle Scholar
  11. 11.
    Burke GW, Cirocco R, Roth D, et al (1993) Activated cytokine pattern in hepatorenal syndrome: Fall in levels after successful orthotopic liver transplantation. Transplant Proc 25: 1876–1877Google Scholar
  12. 12.
    Gerbes AL, Gülber V, Bilzer M (1998) Endothelin and other mediators in the pathophysiology of portal hypertension. Digestion 59 (suppl 2): 8–10PubMedCrossRefGoogle Scholar
  13. 13.
    Wong F, Massie D, Hsu P, Dudley F (1994) Dose dependent effects of oral misoprostol on renal function in alcoholic cirrhosis. Gastroenterology 106: 658–663PubMedGoogle Scholar
  14. 14.
    Peschl L (1978) Klinische and experimentelle Untersuchungen über die Wirkung von Dopamin auf die Hämodynamik and Funktion von Niere and Leber. Wien Klein Wochenschr 86: 1–33Google Scholar
  15. 15.
    Bennet WM, Keeffe E, Melnyk C, et al (1975) Response to dopamine hydrochloride in the hepatorenal syndrome. Arch Intern Med 135: 964–970CrossRefGoogle Scholar
  16. 16.
    Lenz K, Hörtnagl H, Druml W, et al (1991) Ornipressin in the treatment of functional renal failure in decompensated liver cirrhosis. Gastroenterology 101: 1060–1067PubMedGoogle Scholar
  17. 17.
    Guevara M, Gines P, Fernandez-Esparach G, et al (1998) Reversibility of hepatorenal syndrome by prolonged administration of ornipressin and volume expansion. Hepatology 27: 35–41PubMedCrossRefGoogle Scholar
  18. 18.
    Guevara M, Gines P, Bnadi JC, et al (1998) Transjugular intrahepatic portosystemic shunt in hepatorenal syndrome: effects on renal function and vasoactive systems. Hepatology 28: 590–592CrossRefGoogle Scholar
  19. 19.
    Brensing KA, Textor J, Perz J, et al (2000) Long term outcome after transjugular intrahepatic portosystemic stent-shunt in non transplant cirrhotics with hepatorenal syndrome: A phase II study. Gut 47: 288–295Google Scholar
  20. 20.
    Holt S, Goodier D, Marley R (1999) Improvement in renal function in hepatorenal syndrome with N-acetylcysteine. Lancet 353: 294–295PubMedCrossRefGoogle Scholar
  21. 21.
    Heinemann A, Wachter CH, Fickert P, Trauner M, Stauber RE (1998) Vasopressin reverses mesenteric hyperemia and vasoconstrictor hyperresponsivness in anesthetized portal hypertensive rats. Hepatology 27: 646–654CrossRefGoogle Scholar
  22. 22.
    Schmid GP, Abbound FM, Wendling MG, et al (1994) Regional vascular effects of vasopressin: plasma levels and circulatory responses. Am J Physiol 227: 998–1004Google Scholar
  23. 23.
    Ganger DR, Gottstein J, Blei AT (1988) Hemodynamic and renal effects of atrial natriuretic factor in portal hypertensive rats. Potentiation by Phe-Ile-Orn-vasopressin. J Pharmacol Exp Ther 246: 941–945Google Scholar
  24. 24.
    Gadano A, Moreau R, Vachiery F, et al (1997) Natriuretic response to the combination of atrial natriuretic peptide and terlipressin in patients with cirrhosis and refractory ascites. J Hepatol 26: 1229–1234PubMedCrossRefGoogle Scholar
  25. 25.
    Akriviadis E, Botla R, Briggs W, Han S, Reynolds T, Shakil 0 (2000) Pentoxifyllin improves short term survival in severe acute alcoholic hepatitis: A double blind, placebo controlled trial. Gastroenterology 119: 1637–1648Google Scholar
  26. 26.
    Barriere E, Tazi KA, Poirel O, Lebrec D, Moreau R (2001) Terlipressin administration decreases iNOS expression and improves circulatory and liver dysfunction in endotoxin-challenged rats with cirrhosis. J Hepatol 34 (Suppl 1 ): 61 (Abst)Google Scholar
  27. 27.
    Fernando B, Marley R, Holt S, et al (1998) N-acetylcysteine prevents development of the hyperdynamic circulation in the portal hypertensive rat. Hepatology 28: 689–694PubMedCrossRefGoogle Scholar
  28. 28.
    Chin-Dusting JPF, Rasaratnam B, Jennings GLR, Dudley FJ (1997) Effect of fluoroquinolone on the enhanced nitric oxide induced peripheral vasodilation seen in cirrhosis. Ann Intern Med 127: 985–988PubMedCrossRefGoogle Scholar
  29. 29.
    Sorkine S, Abraham RB, Szold 0, et al (2001) Role of molecular adsorbent recycling system ( MARS) in the treatment of patients with acute exacerbation of chronic liver failure. Crit Care Med 29: 1332–1336Google Scholar
  30. 30.
    Mitzner S, Stange J, Klammt S, et al (2000) Improvement of hepatorenal syndrome with extracorporeal albumin dialysis MARS: Results of a prospective, randomized, controlled trial. Liver Transplant 6: 277–286Google Scholar

Copyright information

© Springer Science+Business Media New York 2002

Authors and Affiliations

  • K. Lenz
  • C. Kapral
  • N. P. Linz

There are no affiliations available

Personalised recommendations